Financial reports
10-K
2023 FY
Annual report
29 Mar 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
10-Q
2023 Q2
Quarterly report
11 Aug 23
10-Q
2023 Q1
Quarterly report
12 May 23
10-K
2022 FY
Annual report
17 Apr 23
NT 10-K
Notice of late annual filing
31 Mar 23
10-Q
2022 Q3
Quarterly report
14 Nov 22
Current reports
8-K
Shareholder Nominations Pursuant to Exchange Act Rule 14a-11
15 Apr 24
8-K
Oragenics Appoints James Kelly MD, Chief Medical Officer to Lead Phase II Clinical Trials for Treating Concussion
18 Mar 24
8-K
Oragenics Announces Closing of Public Offering
1 Mar 24
8-K
Oragenics Announces Pricing of Public Offering
28 Feb 24
8-K
Oragenics Announces Proposed Public Offering
27 Feb 24
8-K
Oragenics, Inc. Announces Leadership Transition
12 Feb 24
8-K
Oragenics, Inc. Announces Expiration of Its Investment Banking Engagement Agreement
7 Feb 24
8-K
Other Events
5 Feb 24
8-K
Oragenics Announces Termination of At-The-Market Offering Program
23 Jan 24
8-K
Other Events
16 Jan 24
Registration and prospectus
424B5
Prospectus supplement for primary offering
29 Feb 24
FWP
Free writing prospectus
27 Feb 24
424B5
Prospectus supplement for primary offering
27 Feb 24
FWP
Free writing prospectus
16 Jan 24
424B5
Prospectus supplement for primary offering
16 Jan 24
S-8
Registration of securities for employees
10 Jan 24
D
$850.00 k in equity, sold $850.00 k, 2 investors
7 Aug 23
424B5
Prospectus supplement for primary offering
24 Feb 23
S-3
Shelf registration
13 Jan 23
424B5
Prospectus supplement for primary offering
20 Apr 22
Proxies
DEFA14A
Additional proxy soliciting materials
16 Nov 23
DEFA14A
Additional proxy soliciting materials
2 Nov 23
DEFA14A
Additional proxy soliciting materials
30 Oct 23
DEF 14A
Definitive proxy
30 Oct 23
PRE 14A
Preliminary proxy
6 Oct 23
DEF 14A
Definitive proxy
31 Oct 22
PRE 14A
Preliminary proxy
30 Sep 22
DEFA14A
Additional proxy soliciting materials
26 Jan 22
DEFA14A
Additional proxy soliciting materials
23 Nov 21
DEF 14A
Definitive proxy
13 Oct 21
Other
EFFECT
Notice of effectiveness
26 Jan 23
CORRESP
Correspondence with SEC
23 Jan 23
UPLOAD
Letter from SEC
19 Jan 23
UPLOAD
Letter from SEC
8 Aug 22
CORRESP
Correspondence with SEC
29 Jul 22
UPLOAD
Letter from SEC
20 Jul 22
EFFECT
Notice of effectiveness
8 Jul 20
CORRESP
Correspondence with SEC
26 Jun 20
CORRESP
Correspondence with SEC
19 Jun 20
UPLOAD
Letter from SEC
15 Jun 20
Ownership
SC 13G
Lind Global Fund II LP
6 Mar 24
SC 13D
Odyssey Health, Inc.
12 Feb 24
5
ROBERT C KOSKI
22 Jan 24
4
J MICHAEL REDMOND
2 Jan 24
3
J MICHAEL REDMOND
2 Jan 24
4
Fred Telling
1 Dec 23
144
Notice of proposed sale of securities
30 Nov 23
4
JOHN P GANDOLFO
6 Oct 23
4
Bruce A. Sr. Cassidy
6 Oct 23
3
JOHN P GANDOLFO
6 Oct 23